Worldwide Brings Multidisciplinary Collaboration to Your Severe Combined Immunodeficiency Study
Severe combined immunodeficiency (SCID) is a potentially life-threatening congenital condition characterized by absence of both T-lymphocytes and B-lymphocytes. Due to its heterogeneity, current treatments are varied according to subgroup. Because SCID is a rare disease that is typically detected through newborn screening, researchers face challenges related to the vulnerability of the patient population, as well as the added level of attention required to facilitate caregiver participation.
For your best shot at patient recruitment and complex study design, you’ll want a CRO partner like Worldwide Clinical Trials. A world leader in both IMID and rare disease research, we can provide collaborative support among our core specialty groups. Our relationships with thought leaders, academic research organizations, and patient advocacy groups ensure that we stay apprised of new research developments that could affect your ongoing study. This multidisciplinary approach enables us to take a big-picture view of IMID conditions, ensuring your study design is keenly focused on the end points you need. From Phase I-IV clinical trials to real-world evidence studies, count on Worldwide Clinical Trials.